Related Experiment Videos
Pulmonary function testing and pulmonary Langerhans cell histiocytosis
Cecilia Bernstrand1, Kerstin Cederlund, Jan-Inge Henter
1Childhood Cancer Research Unit, Department of Woman and Child Health, Karolinska University Hospital, Stockholm, Sweden.
Pediatric Blood & Cancer
|December 1, 2005
Summary
Pulmonary Langerhans cell histiocytosis (LCH) patients with extensive lung abnormalities show decreased diffusing capacity and total lung capacity. Pulmonary function testing complements imaging for monitoring this rare lung disease.
Area of Science:
- Pulmonology
- Radiology
- Histiocytosis
Background:
- Pulmonary Langerhans cell histiocytosis (LCH) is a rare disease characterized by the proliferation of Langerhans cells in the lungs.
- Long-term follow-up is crucial for understanding disease progression and management.
Purpose of the Study:
- To investigate the utility of pulmonary function testing (PFT) and high-resolution computed tomography (HRCT) in monitoring pulmonary LCH.
- To correlate HRCT findings with PFT parameters over a median of 16 years.
Main Methods:
- A long-term, single-center study involving patients with pulmonary LCH.
- Assessment included high-resolution computed tomography (HRCT) and pulmonary function testing (PFT).
- Analysis focused on parameters like diffusing capacity corrected for alveolar volume (K(CO)), total lung capacity (TLC), forced expiratory volume in 1 second (FEV1.0), and vital capacity (VC).
Main Results:
- Significant decreases in K(CO) (P=0.016) and TLC (P=0.030) were observed in patients with extensive HRCT abnormalities.
- Patients with late-stage HRCT findings showed increased FEV1.0 (P=0.037) and VC (P=0.036).
Conclusions:
- Pulmonary function testing, particularly diffusing capacity, is a valuable tool for monitoring pulmonary LCH.
- PFT serves as a useful complement to imaging in assessing disease status and progression in pulmonary LCH.